{"id":37110,"date":"2026-03-05T22:06:35","date_gmt":"2026-03-06T03:06:35","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37110"},"modified":"2026-03-05T22:06:38","modified_gmt":"2026-03-06T03:06:38","slug":"the-drug-name-decoder-a-complete-guide-to-generic-pharmaceutical-naming","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-drug-name-decoder-a-complete-guide-to-generic-pharmaceutical-naming\/","title":{"rendered":"The Drug Name Decoder: A Complete Guide to Generic Pharmaceutical Naming"},"content":{"rendered":"\n

The Name Behind the Molecule<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Every drug in clinical use has at least three names. There is the brand name, the one plastered across television commercials and patient assistance program brochures. There is the chemical name, a systematic IUPAC descriptor that tells a trained chemist exactly which atoms are bonded to which, but that no physician, pharmacist, or patient could reasonably memorize. And then there is the generic name – the one that appears on every prescription bottle once patent protection expires, the one that regulatory agencies use in their official publications, and the one that, for professionals working in pharmaceutical IP, competitive intelligence, and drug development, carries the most information per syllable of anything printed on that bottle.<\/p>\n\n\n\n

Generic drug names are not arbitrary. They are engineered artifacts, the product of an internationally coordinated nomenclature system that embeds pharmacological class, molecular mechanism, and sometimes even structural chemistry directly into pronounceable syllables. The stem “-pril” tells you a drug inhibits angiotensin-converting enzyme before you have read another word about it. The stem “-mab” tells you a drug is a monoclonal antibody. The stem “-tinib” tells you it is a kinase inhibitor. A fluent reader of pharmaceutical naming conventions can glance at a new drug name and infer its therapeutic category, its likely mechanism of action, its structural class, and often its origin – all before consulting a single clinical resource.<\/p>\n\n\n\n

This competence is not a soft skill. For IP analysts tracking competitive pipelines through platforms like DrugPatentWatch, where patent data is organized in part by the generic names of covered drugs, the ability to read naming conventions fluently is a research accelerant. For patent attorneys arguing about claim scope, understanding whether a name reflects a structural class or only a functional one affects how broadly claims can be read. For regulatory strategists assessing which Orange Book listings are defensible, knowing that a drug’s INN status predates a patent’s filing date is directly relevant to prior art analysis.<\/p>\n\n\n\n

This guide covers the entire architecture of pharmaceutical generic naming – where names come from, how they are constructed, what their components mean, how they interact with patent strategy and drug regulation, and where the system breaks down in ways that create safety risks and competitive opportunities alike.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\n\n\n\n

The Three-Name Problem: Why Generic Names Exist<\/h2>\n\n\n\n

Chemical Names and Their Practical Limits<\/h3>\n\n\n\n

The IUPAC chemical name for atorvastatin – the world’s best-selling pharmaceutical for much of the 2000s – is (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid [1]. This name is precise. It describes the molecule completely. It is also sixteen syllables of chemical notation that no cardiologist prescribes, no pharmacist dispenses, and no patient requests.<\/p>\n\n\n\n

IUPAC nomenclature was never designed for clinical use. It was designed to give chemists a universal language for describing molecular structures unambiguously. Its precision is its value in the laboratory and in patent claims, where chemical entities must be characterized with sufficient specificity to support enablement and written description. Outside the laboratory, the same precision becomes an obstacle.<\/p>\n\n\n\n

Brand Names and Their Commercial Motivations<\/h3>\n\n\n\n

Pharmaceutical brand names – Lipitor, Nexium, Humira, Keytruda – are marketing constructs. They are selected through focus groups and trademark searches to convey positive associations, to be easily remembered, and to differentiate the product from competitors. They are legally protected trademarks. When a pharmaceutical company’s patent on the underlying molecule expires, generic manufacturers enter the market under the molecule’s generic name, not the original brand name.<\/p>\n\n\n\n

Brand names are deliberately unrelated to pharmacology. Nexium tells you nothing about proton pump inhibition. Humira (Human Monoclonal Antibody in Rheumatoid Arthritis) is an exception – an acronym that happens to describe the drug – but the trend is toward invented words chosen for their commercial characteristics. This opacity is a feature from the marketer’s perspective and a liability from every other perspective.<\/p>\n\n\n\n

Generic Names as Information Architecture<\/h3>\n\n\n\n

The generic name – technically called the nonproprietary name, or the International Nonproprietary Name (INN) when assigned by the World Health Organization – occupies the middle ground between chemical precision and commercial convenience. It is pronounceable. It is drug-class-specific. It is stable across markets and regulatory jurisdictions. It belongs to no single company.<\/p>\n\n\n\n

The WHO’s INN program, established in 1950 [2], has assigned nonproprietary names to more than 12,000 pharmaceutical substances. Every name is deliberately constructed to carry embedded information about the drug’s pharmacological properties through systematic use of standardized syllabic fragments called stems, infixes, and prefixes. Understanding this construction is the foundation of pharmaceutical nomenclature literacy.<\/p>\n\n\n\n

\n\n\n\n

The Architecture of the INN System<\/h2>\n\n\n\n

International Nonproprietary Names: The Global Standard<\/h3>\n\n\n\n

The WHO Expert Committee on Pharmaceutical Preparations publishes INN lists that constitute the internationally recognized generic names for pharmaceutical substances. These names are the default designation used in regulatory filings, scientific publications, pharmacopeial monographs, and prescribing references across over 150 countries.<\/p>\n\n\n\n

The legal status of INNs varies by jurisdiction. In the United States, the equivalent designation is the United States Adopted Name (USAN), maintained by the American Medical Association’s USAN Council. In the United Kingdom, it is the British Approved Name (BAN). In Japan, it is the Japanese Approved Name (JAN). These national designations are largely harmonized with INN – in most cases they are identical – but historically they diverged, and legacy literature contains numerous instances where the same molecule carries different names in different countries. Paracetamol (INN\/BAN) and acetaminophen (USAN) are the most widely known example of this divergence [3].<\/p>\n\n\n\n

For practical purposes, analysts working primarily in U.S. regulatory and patent contexts use USAN as the operative name. For international competitive intelligence and global patent family analysis, INN is the correct standard.<\/p>\n\n\n\n

The USAN Council: How America Names Drugs<\/h3>\n\n\n\n

The USAN Council was established in 1961 as a joint venture between the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmacists Association, with the FDA as a cooperating federal agency [4]. Its mandate is to assign simple, informative, and unique nonproprietary names to drugs intended for use in the United States.<\/p>\n\n\n\n

The Council operates on a request-and-review model. A company developing a new drug substance submits a USAN application, proposing one or more candidate names and providing the pharmacological data needed to classify the drug. The Council’s staff reviews the application, assigns appropriate stems and infixes, verifies that the proposed name does not conflict with existing names, and publishes the new USAN in the AMA’s journals.<\/p>\n\n\n\n

The Council’s guidelines specify that USANs should be “simple and reasonably informative about pharmacological or chemical relationships without being excessively long” [5]. In practice, this means names should be pronounceable in one reading, should contain the relevant class stem, and should avoid syllabic combinations that could be confused with existing names visually or phonetically.<\/p>\n\n\n\n

INN and USAN Alignment: The Coordination Mechanism<\/h3>\n\n\n\n

The WHO INN program and the USAN Council coordinate actively to ensure that a new drug receives the same name internationally whenever possible. A company developing a new drug typically applies to both bodies simultaneously, submitting parallel applications under the WHO’s Recommended INN (rINN) process and the USAN process. In most cases, the resulting names are identical or differ only in minor phonetic adjustments that accommodate pronunciation conventions in different languages.<\/p>\n\n\n\n

Where the names do differ – typically in older drugs assigned before full harmonization – both names appear in regulatory and clinical documentation. For IP purposes, both names should be included in prior art searches, since earlier scientific publications may have used a national designation that differs from the current INN. DrugPatentWatch tracks both INN and USAN designations for covered products, which matters when verifying whether a generic name used in a patent application’s specification corresponds to the same molecule as a subsequently published INN.<\/p>\n\n\n\n

\n\n\n\n

Stems: The Information Embedded in Every Generic Name<\/h2>\n\n\n\n

What a Stem Is and How It Works<\/h3>\n\n\n\n

A stem is a standardized syllabic unit – typically two to five letters – that the WHO and USAN Council assign to specific pharmacological or chemical classes. When a new drug in a class receives its INN or USAN, the relevant stem must be incorporated into the name. This system creates immediate classification information for anyone who has learned the stems.<\/p>\n\n\n\n

Stems are positionally significant. Most appear at the end of a drug name (the suffix position), but some appear at the beginning (prefix) or in the middle (infix). The position is standardized for each stem, so that the same syllable always appears in the same location regardless of what other syllable it is combined with.<\/p>\n\n\n\n

The WHO publishes a consolidated list of INN stems that is periodically updated as new drug classes emerge and require classification. As of the most recent update, the list contains over 400 stems and stem fragments, organized by pharmacological category [6]. This list is the foundational reference document for anyone who needs to decode or construct generic drug names.<\/p>\n\n\n\n

The Mechanics of Name Construction<\/h3>\n\n\n\n

A new drug name is typically constructed by combining a unique prefix (chosen to distinguish the drug within its class) with the relevant class stem. The prefix is invented – it should not have inherent meaning in any major language, should not contain misleading pharmacological information, and should not create confusion with existing names. The stem is standardized.<\/p>\n\n\n\n

For a drug like omeprazole (a proton pump inhibitor), the stem is “-prazole,” which identifies it as a proton pump inhibitor with benzimidazole structure [7]. The prefix “ome-” is the invented distinguishing element. For lansoprazole, the prefix “lans-” does the distinguishing work. For esomeprazole (the S-enantiomer of omeprazole), the prefix “eso-” indicates the enantiomeric relationship to omeprazole, an example of a prefix that actually does carry structural meaning.<\/p>\n\n\n\n

This is not accidental. The INN system specifically permits prefixes to carry structural meaning when that meaning is pharmacologically relevant. The prefixes “levo-,” “dextro-,” “eso-” (for S-enantiomers), and similar chirality markers are accepted and expected. They do not violate the principle against misleading prefixes because the structural information they convey is precise and accurate.<\/p>\n\n\n\n

Stems by Major Therapeutic Category<\/h3>\n\n\n\n

Cardiovascular Stems<\/strong><\/p>\n\n\n\n

The cardiovascular category contains some of the most widely recognized stems in the system, reflecting the historical prominence of cardiovascular pharmacology in twentieth-century drug development.<\/p>\n\n\n\n

The “-olol” stem identifies beta-adrenoreceptor antagonists – propranolol, atenolol, metoprolol, carvedilol (where the “-dil” suffix identifies additional vasodilatory properties) [8]. The characteristic double-l ending is essentially a fingerprint for the class. The “-pril” stem identifies ACE inhibitors – captopril, enalapril, lisinopril, ramipril. The “-sartan” stem identifies angiotensin II receptor antagonists (ARBs) – losartan, valsartan, irbesartan, olmesartan. The “-vastatin” stem identifies HMG-CoA reductase inhibitors (statins) – lovastatin, pravastatin, simvastatin, atorvastatin, rosuvastatin.<\/p>\n\n\n\n

Each of these stems corresponds to a specific mechanism of action. An analyst looking at a new compound named with the “-sartan” suffix knows immediately, without any additional data, that the compound is being developed as an ARB. This has direct implications for patent analysis: the prior art search should cover the full ARB compound class, and the Orange Book listings for competing ARBs should be reviewed for formulation and method-of-treatment patent approaches that the new compound’s developers might replicate.<\/p>\n\n\n\n

The “-dipine” stem identifies dihydropyridine calcium channel blockers – nifedipine, amlodipine, felodipine, lercanidipine. The “-thiazide” (or simply the “-azide” suffix in combinations) identifies thiazide diuretics. The “-kalant” and “-serod” stems identify, respectively, potassium channel modulators and serotonin receptor modulators in the cardiovascular context.<\/p>\n\n\n\n

Anti-infective Stems<\/strong><\/p>\n\n\n\n

Anti-infective nomenclature uses stems to signal both the drug class and, in many cases, the specific pathogen target. This dual-layer information embedding is more explicit in anti-infectives than in almost any other category.<\/p>\n\n\n\n

Among antibacterials, the “-cillin” stem identifies penicillin-class beta-lactams – ampicillin, amoxicillin, piperacillin, dicloxacillin. The “-cef-” or “ceph-” prefix identifies cephalosporin class beta-lactams – cephalexin, cefazolin, ceftriaxone, cefepime. The “-penem” stem identifies carbapenems – imipenem, meropenem, ertapenem, doripenem. The “-cycline” stem identifies tetracycline class antibiotics – doxycycline, minocycline, tigecycline [9].<\/p>\n\n\n\n

Among antifungals, the “-conazole” stem identifies azole antifungals – fluconazole, itraconazole, voriconazole, posaconazole. The mechanism-class correspondence here (azole ring structure, lanosterol 14-alpha-demethylase inhibition) is tight, and the stem has become so well recognized that regulatory reviewers use it as a rapid classification tool.<\/p>\n\n\n\n

Among antivirals, the stem landscape has expanded dramatically with the HIV, hepatitis C, and COVID-19 treatment pipelines. The “-vir” stem is the oldest and broadest antiviral stem – aciclovir, ganciclovir, valaciclovir. Subclass stems have developed within this broader family: “-navir” for HIV protease inhibitors (ritonavir, lopinavir, atazanavir, darunavir), “-vudine” for nucleoside reverse transcriptase inhibitors (zidovudine, lamivudine, emtricitabine), “-fovir” for nucleotide reverse transcriptase inhibitors (tenofovir, adefovir), and “-tegravir” for HIV integrase inhibitors (raltegravir, elvitegravir, dolutegravir, bictegravir) [10].<\/p>\n\n\n\n

For hepatitis C specifically, the “-previr” stem identifies NS3\/4A serine protease inhibitors (telaprevir, boceprevir, simeprevir, grazoprevir, glecaprevir), while the “-asvir” stem identifies NS5A inhibitors (ledipasvir, elbasvir, pibrentasvir, velpatasvir), and the “-buvir” stem identifies NS5B nucleoside polymerase inhibitors (sofosbuvir, dasabuvir). The specificity of these stems makes the hepatitis C pipeline unusually legible in naming terms – a glance at the stem tells you exactly which protein in the viral replication cycle the compound targets.<\/p>\n\n\n\n

CNS Stems<\/strong><\/p>\n\n\n\n

Central nervous system drug naming reflects both mechanistic and structural classifications, with some of the system’s most nuanced stem choices.<\/p>\n\n\n\n

The “-azepam” and “-azolam” stems identify benzodiazepines – diazepam, lorazepam, oxazepam, triazolam, alprazolam, midazolam. The stems reflect the core fused ring structure (1,4-benzodiazepine) that defines the class. The “-barbital” stem identifies barbiturates – phenobarbital, pentobarbital, secobarbital. The “-done” suffix, combined with various prefixes and infixes, appears in several CNS contexts, including for atypical antipsychotics like risperidone, ziprasidone, and lurasidone, though “-done” itself is not a single-class stem.<\/p>\n\n\n\n

For antidepressants, the SSRIs are identified by their class rather than a tightly shared stem, but the “-tine” ending appears prominently – fluoxetine, paroxetine, sertraline (where “-line” appears instead), citalopram (where “-pram” reflects the bicyclic phthalane structure). The SNRIs include venlafaxine and duloxetine, where the “-faxine” and “-oxetine” suffixes reflect structural relationships within the class.<\/p>\n\n\n\n

The “-triptan” stem identifies 5-HT1B\/1D receptor agonists used in migraine treatment – sumatriptan, rizatriptan, zolmitriptan, eletriptan, frovatriptan. This stem is highly specific – the “-triptan” designation tells you exactly the drug class, mechanism, and therapeutic indication without further research.<\/p>\n\n\n\n

For newer CNS targets, the “-gepant” stem has been established for calcitonin gene-related peptide (CGRP) receptor antagonists used in migraine prevention – rimegepant, ubrogepant, atogepant [11]. The rapid adoption of this new stem in the early 2020s illustrates how the naming system expands to accommodate novel drug classes as they emerge from development pipelines.<\/p>\n\n\n\n

Oncology Stems<\/strong><\/p>\n\n\n\n

Oncology has seen the most rapid proliferation of new stems in recent decades, driven by the expansion of targeted therapy and immuno-oncology pipelines. Understanding these stems is essential for anyone tracking pharmaceutical competitive intelligence in the oncology space.<\/p>\n\n\n\n

The “-tinib” stem identifies kinase inhibitors broadly – imatinib, erlotinib, gefitinib, lapatinib, sunitinib, sorafenib. The stem name was deliberately chosen from “inhibitor” to signal the drug’s mechanism. More specific subclass stems have developed for specific kinase targets: “-cetinib” appears in ALK inhibitors (crizotinib identifies ALK and has the “-tinib” suffix, while alectinib and lorlatinib follow the pattern), and the EGFR-specific generation of kinase inhibitors such as osimertinib use the broader “-tinib” stem without a target-specific subgroup stem [12].<\/p>\n\n\n\n

The “-ciclib” stem identifies CDK (cyclin-dependent kinase) inhibitors – palbociclib, ribociclib, abemaciclib, trilaciclib. These drugs inhibit CDK4\/6 and are approved for breast cancer, and the “-ciclib” stem ties them explicitly to the cyclin-dependent kinase inhibitor class.<\/p>\n\n\n\n

The “-rafenib” stem identifies BRAF inhibitors – vemurafenib, dabrafenib, encorafenib. The “-metinib” stem identifies MEK inhibitors – cobimetinib, trametinib, binimetinib. Together, these two stems allow rapid identification of combination therapy partners in the MAPK pathway inhibition space, which is the dominant strategy in BRAF-mutant melanoma.<\/p>\n\n\n\n

The “-lisib” stem identifies PI3K inhibitors – idelalisib, copanlisib, alpelisib. The “-sertib” stem identifies PARP inhibitors – olaparib, niraparib, rucaparib, talazoparib. The “-zomib” stem identifies proteasome inhibitors – bortezomib, carfilzomib, ixazomib.<\/p>\n\n\n\n

For immuno-oncology, the stem picture interacts with the broader biologics naming system, discussed at length in a separate section below.<\/p>\n\n\n\n

Diabetes and Metabolic Disease Stems<\/strong><\/p>\n\n\n\n

The antidiabetic drug category is one of the most crowded in the stem system, reflecting decades of active drug development across multiple mechanistic platforms.<\/p>\n\n\n\n

The “-gliptin” stem identifies DPP-4 (dipeptidyl peptidase-4) inhibitors – sitagliptin, saxagliptin, alogliptin, linagliptin, vildagliptin. The “-gliflozin” stem identifies SGLT2 (sodium-glucose cotransporter-2) inhibitors – empagliflozin, dapagliflozin, canagliflozin, ertugliflozin. The “-glutide” stem identifies GLP-1 receptor agonists – exenatide, liraglutide, semaglutide, dulaglutide, albiglutide.<\/p>\n\n\n\n

The GLP-1 receptor agonist category has attracted enormous commercial and scientific attention since the approval of semaglutide for obesity (brand names Ozempic for diabetes, Wegovy for obesity), and the “-glutide” stem has become one of the most commercially significant name endings in the current pipeline. Any analyst reviewing competitive filings for GLP-1 receptor agonists can use this stem to rapidly identify all INN-named compounds in the class.<\/p>\n\n\n\n

The older “-amide” endings appear in sulfonylureas (glibenclamide, glipizide, glimepiride, though these are structurally characterized rather than sharing a single tight stem), and the biguanide metformin stands alone without a class-specific stem beyond the chemical descriptor “met-” from methylated guanide.<\/p>\n\n\n\n

\n\n\n\n

The INN Application Process: Step by Step<\/h2>\n\n\n\n

Applying for an INN<\/h3>\n\n\n\n

The WHO INN application process requires a pharmaceutical company developing a new drug to submit a formal application to the WHO Secretariat, providing pharmacological data, chemical structure information, and a proposed name that the company wishes to receive consideration [13]. The application should be submitted at least 18 months before the anticipated regulatory filing date to allow sufficient time for the INN assignment and international consultation process.<\/p>\n\n\n\n

The WHO Secretariat reviews the application and proposes a Recommended INN (rINN). The proposed name is published in WHO Drug Information journal for a four-month comment period, during which national health authorities, professional organizations, and the public may submit objections. Objections most commonly concern: phonetic similarity to existing names that could cause medication errors, claimed trademark conflicts, cultural inappropriateness in specific languages, or structural errors in the stem assignment.<\/p>\n\n\n\n

After the comment period, the WHO considers any objections and either adopts the proposed rINN as a final INN or issues a modified name. The final INN is published in the WHO’s Cumulative List of International Nonproprietary Names for Pharmaceutical Substances.<\/p>\n\n\n\n

The Parallel USAN Process<\/h3>\n\n\n\n

In the United States, a company seeking USAN designation submits a separate application to the USAN Council. The submission includes the proposed name, pharmacological data sufficient to classify the substance, and confirmation that no patent or trademark conflicts exist for the proposed name in the United States.<\/p>\n\n\n\n

The USAN Council’s staff evaluates the submission against its Statement on Nonproprietary Nomenclature requirements, assigning stems from the AMA’s stem list and verifying that the proposed name satisfies the requirements for uniqueness and pronounceability. If the name is accepted with modifications, the staff negotiates with the company to reach an agreed-upon USAN. If the name conflicts seriously with the proposed INN, coordination with the WHO occurs to resolve the difference before either name is finalized.<\/p>\n\n\n\n

The USAN Council publishes new names in JAMA Network Open and in the AMA’s drug database. Publication constitutes the adoption of the USAN, and the name then becomes the official nonproprietary designation for that substance in U.S. regulatory and clinical contexts.<\/p>\n\n\n\n

Objections and the Name Conflict Process<\/h3>\n\n\n\n

The most common basis for a successful objection to a proposed INN is phonetic or orthographic similarity to an existing drug name. The WHO and USAN Council maintain proprietary lists of proposed and existing names and run systematic comparison algorithms to identify potentially confusing name pairs. The Institute for Safe Medication Practices (ISMP) and the FDA also participate in safety screening, flagging name pairs that, when handwritten or verbally communicated, could be misread as the other [14].<\/p>\n\n\n\n

When a similarity is identified, the proposing company must either modify the proposed name or demonstrate that the similarity does not create a realistic confusion risk. The threshold is not theoretical confusion but practical, context-specific confusion in clinical settings where errors are most likely – verbal prescription orders, handwritten prescriptions, and automated dispensing system lookups. The FDA’s Division of Medication Error Prevention and Analysis (DMEPA) independently reviews names for error potential under its Pharmacy, Orthographic, Clinical, and Auditory (POCA) assessment framework [15].<\/p>\n\n\n\n

The trademark dimension adds a separate conflict pathway. Generic names cannot incorporate trademark-protected syllables belonging to another company, and they cannot be names that could themselves be registered as trademarks. The WHO and USAN Council require that companies confirm trademark clearance before a name is finalized. This can create delays when proposed names contain syllables that an unrelated company has incorporated into a registered brand name, even in a non-pharmaceutical context.<\/p>\n\n\n\n

\n\n\n\n

Biologics and the Naming Revolution<\/h2>\n\n\n\n

Why Biologics Required a New System<\/h3>\n\n\n\n

The naming framework described above was developed primarily for small-molecule drugs – organic compounds with defined chemical structures, predictable synthetic pathways, and discrete molecular identities. The expansion of biotechnology-derived medicines (biologics) into clinical use from the 1980s onward exposed the limits of the traditional stem system in ways that required systematic reform.<\/p>\n\n\n\n

Biologics include monoclonal antibodies, recombinant proteins, blood products, vaccines, and cellular therapies. These are large, complex molecules manufactured in living cells, with molecular weights measured in thousands to hundreds of thousands of Daltons. Their “structure” – insofar as that concept applies in the same way as for small molecules – includes not just the amino acid sequence but post-translational modifications, glycosylation patterns, and higher-order folding that cannot be fully described by any conventional chemical name.<\/p>\n\n\n\n

The INN system addressed biologics by developing class-specific stems and a distinct naming architecture that encodes information about target, source, and structure without attempting to describe the molecule in the exhaustive way IUPAC nomenclature would require.<\/p>\n\n\n\n

Monoclonal Antibody Naming: The Pre-2021 Architecture<\/h3>\n\n\n\n

For monoclonal antibodies (mAbs), the INN system developed a systematic naming architecture that, by the 2010s, had become one of the most widely recognized naming conventions in all of pharmacology. The original system, in use from roughly 1990 to 2021, used four components: a prefix, a disease\/target substem, a source substem, and the suffix “-mab” [16].<\/p>\n\n\n\n

The “-mab” suffix identified the molecule as a monoclonal antibody universally. Within the name, the source substem indicated the species origin of the antibody:<\/p>\n\n\n\n

“-u-” for fully human antibodies (adalimumab, golimumab, ipilimumab, denosumab).<\/p>\n\n\n\n

“-zu-” or “-z-” for humanized antibodies (bevacizumab, trastuzumab, omalizumab, pembrolizumab).<\/p>\n\n\n\n

“-xi-” for chimeric antibodies (cetuximab, infliximab, rituximab, basiliximab).<\/p>\n\n\n\n

“-o-” or “-omo-” for fully murine antibodies, a rare classification in modern approved drugs given the immunogenicity risks of murine antibodies in humans.<\/p>\n\n\n\n

The disease\/target substem specified the therapeutic target or clinical application: “-li-” for immunological targets, “-tu-” for tumor targets, “-ci-” for cardiovascular targets, “-vi-” for viral targets, “-ba-” for bacterial targets. This gave a trained reader the combination of target class and species origin embedded in the center of every monoclonal antibody INN.<\/p>\n\n\n\n

The system worked remarkably well for the first generation of approved monoclonal antibodies. It begins to break down as the number of approved antibodies grew exponentially. With hundreds of antibodies approved and thousands in development, the number of distinguishable two-to-three letter prefixes available within each target-source combination became limiting. Names grew longer and more phonetically awkward. Multiple antibodies in the same target-source combination required increasingly similar prefixes, creating precisely the confusion-risk problem the system was designed to prevent.<\/p>\n\n\n\n

The 2021 Reform: A Simplified Monoclonal Antibody System<\/h3>\n\n\n\n

The WHO implemented a revised monoclonal antibody naming system in 2021 that substantially simplified the architecture while preserving the information content that mattered most for clinical and regulatory use [17].<\/p>\n\n\n\n

Under the revised system, the source substem was eliminated. The WHO’s decision rested on two realities: first, antibody engineering had progressed to the point where the chimeric\/humanized\/human distinction had diminished clinical significance, with most modern antibodies being either fully human or highly humanized; second, the elimination of the source substem freed up naming space that had been exhausted in many target classes.<\/p>\n\n\n\n

The revised architecture retains the “-mab” suffix and a prefix, but replaces the compound substem with a single target-class substem drawn from a new, streamlined list. The new target substems include “-li-” (general immunological targets, retained), “-ta-” (tumor antigens including receptor targets), “-ne-” (neural targets), “-ci-” (cardiovascular and hematologic targets), “-ki-” (interleukin targets), and several others reflecting the major therapeutic target categories in current antibody development programs [18].<\/p>\n\n\n\n

For already-named antibodies, the old names remain valid and will not be changed. The reform applies prospectively to new INNs assigned after the effective date. This creates a transitional period in which the pharmaceutical literature contains a mixture of old-system and new-system monoclonal antibody names, which analysts need to be aware of when interpreting clinical and patent literature.<\/p>\n\n\n\n

Antibody-Drug Conjugates and Bispecifics: New Extensions<\/h3>\n\n\n\n

The INN system has had to adapt further to accommodate two categories of engineered antibodies that do not fit the standard mAb architecture: antibody-drug conjugates (ADCs) and bispecific antibodies.<\/p>\n\n\n\n

ADCs combine a monoclonal antibody with a cytotoxic small molecule payload through a chemical linker, creating a targeted drug delivery system. Their names use the standard monoclonal antibody architecture but add “-tansine,” “-vedotin,” “-deruxtecan,” or other payload-identifying suffixes that indicate the nature of the conjugated cytotoxic agent [19]. Ado-trastuzumab emtansine (Kadcyla) carries the “-emtansine” suffix identifying its maytansine-class cytotoxic payload. Brentuximab vedotin carries “-vedotin” identifying its auristatin-class payload.<\/p>\n\n\n\n

Bispecific antibodies bind two different antigens simultaneously – either on the same cell or on different cell types. Their INN construction uses the “-mab” suffix but incorporates components from the naming of both target specificities, creating compound names that can be difficult to parse initially but follow consistent logical rules once the conventions are understood [20]. Blinatumomab, a bispecific T-cell engager (BiTE) targeting CD19 on tumor cells and CD3 on T cells, predates the formal bispecific naming conventions and was named under older conventions. More recent bispecifics like amivantamab (targeting EGFR and MET) and mosunetuzumab (CD3 and CD20) follow the updated framework.<\/p>\n\n\n\n

\n\n\n\n

Biosimilar Naming: The FDA’s Policy Fight<\/h2>\n\n\n\n

The Distinguishable Name Requirement<\/h3>\n\n\n\n

When a follow-on biologic (biosimilar) enters the market, a question arises that has no exact parallel in small-molecule generic drug naming: should the biosimilar have the same INN as the reference product, or a distinct nonproprietary name?<\/p>\n\n\n\n

For small-molecule generics, the answer has always been “same name.” Generic atorvastatin has the same nonproprietary name as branded Lipitor. This is the entire point of the nonproprietary name system – one name for one drug substance, regardless of manufacturer. The same logic applied to biologics would give all biosimilars the same INN as their reference products.<\/p>\n\n\n\n

The FDA rejected this logic for biologics. In 2015, the agency published draft guidance proposing that biosimilars receive a nonproprietary name consisting of the reference product’s INN plus a randomly assigned four-letter distinguishing suffix [21]. The suffix would be meaningless in pharmacological terms – drawn from a list of pronounceable letter combinations – but would create a distinct designation that would appear in electronic health records, pharmacy dispensing records, and adverse event reports.<\/p>\n\n\n\n

The FDA’s rationale was pharmacovigilance. Because biologics are manufactured in living cells and are sensitive to manufacturing process changes, the FDA argued that precise tracking of which specific product a patient received was essential for safety monitoring. If a patient on an originator biologic experienced an adverse event, and an identically-named biosimilar was being dispensed by other pharmacists, attributing the event to the correct product would be more difficult without distinguishing names.<\/p>\n\n\n\n

Industry Opposition and the Final Rule<\/h3>\n\n\n\n

The distinguishable suffix policy generated substantial opposition from two directions. Generic and biosimilar manufacturers, along with patient advocacy organizations focused on access, argued that different names for therapeutically equivalent products would create clinical hesitancy about biosimilar substitution, slow adoption, and preserve brand drug revenues that the BPCIA’s competitive framework was designed to erode [22]. They pointed to the European Medicines Agency’s experience, where biosimilars had achieved substantial market penetration without distinguishing name requirements.<\/p>\n\n\n\n

Originator manufacturers largely supported the policy, arguing that pharmacovigilance considerations were genuine and that distinguishing names would protect patient safety. The fact that the policy also happened to support continued market differentiation between originator products and biosimilars was not lost on analysts.<\/p>\n\n\n\n

The FDA finalized its suffix policy in 2017, requiring four-letter suffixes for both biosimilars and their reference products. Adalimumab-adaz (Hyrimoz), adalimumab-adbm (Cyltezo), and adalimumab-atto (Amjevita) all carry their distinguishing four-letter suffixes alongside the shared adalimumab INN. The reference product, Humira, was retroactively given the suffix adalimumab-atto designation as the originator.<\/p>\n\n\n\n

Patent and Regulatory Implications of Biosimilar Naming<\/h3>\n\n\n\n

The distinguishing suffix system has practical consequences that extend beyond pharmacovigilance into IP and competitive strategy.<\/p>\n\n\n\n

In Orange Book listings – which cover small-molecule drugs – there is a straightforward one-to-one relationship between the listed drug name and the patents covering it. In the Purple Book, the FDA’s equivalent listing for biologics, the product name structure now requires manufacturers to track both the base INN and the suffix when searching for reference product listings and associated patents.<\/p>\n\n\n\n

DrugPatentWatch’s coverage of biological products under the BPCIA framework includes suffix-level product identification, which is necessary for tracking the patent position of individual biosimilar products rather than the reference product class as a whole. The patent dance under the BPCIA, in which reference product sponsors and biosimilar applicants exchange patent lists, is product-specific. Two biosimilars of the same reference product may have different patent dispute profiles if they use different formulations or manufacturing processes – and their distinguishing suffixes make them individually trackable in regulatory databases.<\/p>\n\n\n\n

For competitive intelligence purposes, the suffix system also creates a visible pipeline tracker. When the FDA assigns a suffix to a biosimilar that has not yet been approved, the assignment is a signal that regulatory review is advanced. Monitoring FDA suffix assignments – which are published in the agency’s biosimilar product list – provides advance notice of impending competitive entry.<\/p>\n\n\n\n

\n\n\n\n

Generic Drug Naming and Patent Strategy<\/h2>\n\n\n\n

How Naming Status Affects Prior Art<\/h3>\n\n\n\n

The date on which a drug substance receives its INN or USAN designation is a legally material date for patent purposes. An INN designation constitutes a public disclosure of the drug’s name, pharmacological class, and, through the stem system, its mechanistic category. This public disclosure can have prior art implications for subsequent patent applications claiming compounds in the same class.<\/p>\n\n\n\n

Specifically, if a compound receives an INN in January of year one, and a competitor files a patent application in year two claiming a genus of compounds that includes the INN-designated compound’s structural class, the INN publication is prior art against the year-two application under 35 U.S.C. \u00a7 102 [23]. The INN list entry does not provide the full chemical structure (that requires cross-referencing to the formal INN submission, which is more detailed), but it provides enough class information to support an obviousness argument.<\/p>\n\n\n\n

For patent drafters, this means the timing of INN application submission relative to patent filing is strategically significant. Filing patent applications before submitting INN applications preserves the patent application’s priority date against subsequent INN-based disclosure arguments. The reverse sequence – INN designation before patent filing – can create complications that must be addressed in prosecution.<\/p>\n\n\n\n

INN Stems as Claim Scope Indicators<\/h3>\n\n\n\n

For patent examiners and litigators conducting prior art searches, INN stems provide a rapid classification tool that can identify the relevant patent art more efficiently than text-based searching alone.<\/p>\n\n\n\n

A prior art search for patents covering a new “-tinib” kinase inhibitor should systematically review existing INNs in the “-tinib” class, because prior INN assignments indicate prior FDA-reviewed disclosure of compounds in the same mechanistic class. If three earlier “-tinib” compounds had their INNs assigned before the patent filing date, and their INN submissions disclosed the pharmacological class and relevant SAR data, those submissions constitute a potentially relevant prior art corpus regardless of whether they appear in formal patent literature.<\/p>\n\n\n\n

DrugPatentWatch’s integration of INN\/USAN designations with patent data provides analysts with the cross-referencing capability to identify this type of prior art efficiently. The platform links drug names (including nonproprietary names across their historical variants) to associated patents, which means analysts can search by stem category to identify the patent portfolio landscape for an entire drug class simultaneously.<\/p>\n\n\n\n

Orange Book Linkage and the Generic Name Standard<\/h3>\n\n\n\n

The FDA’s Orange Book lists patents by the brand name of the drug product, but the underlying drug substance is identified by its nonproprietary name. ANDA filers submit applications under the drug product’s nonproprietary name (or its active ingredient designations), and Orange Book patent listings are maintained by reference to the nonproprietary name.<\/p>\n\n\n\n

When a generic manufacturer submits a Paragraph IV certification challenging Orange Book patents, the certification is filed under the nonproprietary name. The 30-month stay that triggers on litigation relates to the patent’s coverage of the drug product designated by its nonproprietary name. This means that any ambiguity in nonproprietary name designation – for example, where a drug has both an older national name and a harmonized INN that differ slightly – can create procedural complications in Paragraph IV proceedings.<\/p>\n\n\n\n

For compound drugs (two or more active ingredients), each component has its own nonproprietary name, and the combination product’s regulatory designation must accurately reference both. Patent claims in Orange Book-listed combination product patents often use the nonproprietary names of both active ingredients, and claim construction analysis in litigation may require interpreting the scope of claims drafted using those names against the regulatory definitions of each component.<\/p>\n\n\n\n

\n\n\n\n

International Naming Conflicts and Variations<\/h2>\n\n\n\n

The Historical Divergence Problem<\/h3>\n\n\n\n

Before full INN-USAN harmonization, many drugs acquired different nonproprietary names in different countries. The most common source of divergence was differing phonetic preferences and translation conventions. In British English, the “-ae” digraph (as in adrenaline) was preferred where American English would use “-e” alone (epinephrine). Latin naming conventions used by the British Pharmacopoeia differed systematically from the Greek-derived conventions preferred by the American pharmacopoeial system.<\/p>\n\n\n\n

The WHO’s harmonization program has resolved most active divergences for drugs approved in the past three decades, but legacy names remain in clinical use and appear in historical literature. Analysts reviewing clinical trials, scientific publications, and patent applications from before 1995 should be aware that drug names may need to be verified against INN lists to confirm identity with the substances currently known by different names.<\/p>\n\n\n\n

Some historically significant divergences include: adrenaline (INN\/BAN) versus epinephrine (USAN); paracetamol (INN\/BAN) versus acetaminophen (USAN); frusemide (older BAN) versus furosemide (current INN\/USAN); lignocaine (older BAN) versus lidocaine (current INN\/USAN) [24]. In clinical settings, these divergences create persistent confusion risks that WHO harmonization has reduced but not eliminated.<\/p>\n\n\n\n

Modified INNs: Salts, Esters, and Prodrugs<\/h3>\n\n\n\n

The INN assigned to a drug substance refers to the active pharmaceutical ingredient in its free base or free acid form. When the drug is formulated as a salt (to improve solubility or stability) or as an ester or prodrug (to improve bioavailability or tissue distribution), the salt or ester form receives a Modified INN (INNM), constructed by appending the salt or ester name to the INN.<\/p>\n\n\n\n

Enalapril (INN) becomes enalapril maleate (INNM) in its maleate salt form. Amlodipine (INN) becomes amlodipine besylate (INNM) in its benzenesulfonate salt form used in the marketed product. Valaciclovir (INN) is itself a prodrug of aciclovir – its name reflects its relationship to aciclovir through the “val-” prefix indicating the L-valine ester prodrug structure.<\/p>\n\n\n\n

INNM assignments are important for patent analysis because patents on salt forms are distinct from patents on the free base compound. A compound patent covering the free base does not necessarily cover every salt form of that compound – or it does, but demonstrating infringement requires showing that the salt form is converted to the free base in vivo in a way that places the infringing product within the claim scope. This was precisely the legal issue in several Paragraph IV disputes involving salt form patents, where defendants argued that their specific salt form was not the salt form claimed in the Orange Book patent [25].<\/p>\n\n\n\n

Country-Specific Name Variations in Regulatory Filings<\/h3>\n\n\n\n

For international patent portfolio management, the fact that drug names can vary across jurisdictions creates a data quality problem in patent family tracking. A European patent application may identify the active ingredient by its BAN or INN while the corresponding U.S. application uses USAN, and a Japanese application uses JAN. If the three names differ, automated cross-referencing systems may fail to recognize that the three applications cover the same molecule.<\/p>\n\n\n\n

In patent drafting practice, the solution is to include both the systematic chemical name and any available nonproprietary names in the patent specification, with cross-reference to multiple naming systems. In database analysis, the solution is to use a canonical identifier (such as the InChIKey or CAS number) as the primary molecule identifier and link all nonproprietary name variants to that canonical identifier.<\/p>\n\n\n\n

DrugPatentWatch uses a compound-centric data architecture that normalizes across name variants, reducing the risk of missed patent family connections from naming inconsistencies. For manual verification of critical patents, analysts should independently confirm that the drug names in a patent specification correspond to the correct substance under current INN\/USAN conventions.<\/p>\n\n\n\n

\n\n\n\n

Stems as Competitive Intelligence Tools<\/h2>\n\n\n\n

Reading the Pipeline from Public INN Lists<\/h3>\n\n\n\n

The WHO publishes proposed and recommended INNs in WHO Drug Information, a quarterly journal available to the public [26]. Each issue lists new proposed INNs with their pharmacological classifications and chemical descriptions. Reading these lists systematically gives pharmaceutical competitive intelligence analysts a six-to-twelve month preview of the drug development pipeline, ahead of most clinical trial registrations and well ahead of marketing approval applications.<\/p>\n\n\n\n

The INN application process typically occurs during late preclinical or early clinical development, before the drug has a brand name and often before Phase II results are available. The list of proposed INNs in any given WHO Drug Information issue thus represents a snapshot of what pharmaceutical companies believed was worth pursuing enough to invest in the INN application process – an investment that signals reasonable confidence in eventual regulatory filing.<\/p>\n\n\n\n

For analysts tracking specific drug classes, the proposed INN list is a systematic intelligence source. A WHO Drug Information issue proposing three new “-gepant” compounds with distinct prefixes indicates that at least three companies have CGRP receptor antagonist programs at the INN application stage. This information, combined with DrugPatentWatch’s patent family tracking, allows analysts to map the competitive landscape of a drug class with unusual clarity.<\/p>\n\n\n\n

Predicting Patent Cliff Exposure from Stem Class Analysis<\/h3>\n\n\n\n

The combination of stem-based class identification and patent term data enables a class-level patent cliff analysis that goes beyond individual product tracking. For a given drug class identified by its stem, analysts can use platforms like DrugPatentWatch to pull all Orange Book-listed patents covering drugs in that class, map their expiration dates, and identify the years in which the class as a whole faces generic competition pressure.<\/p>\n\n\n\n

For example, the “-gliflozin” class (SGLT2 inhibitors) has staggered patent expiration timelines across its members: empagliflozin, dapagliflozin, and canagliflozin each have different compound patent filing dates, different PTE awards, and different secondary patent portfolios. A class-level analysis combining stem identification with patent term data reveals that the SGLT2 class faces sequential generic entry opportunities from the mid-2020s through the early 2030s, creating a competitive window for generic manufacturers with compound patent challenges and for branded manufacturers seeking to establish new formulations or combination products before generic entry.<\/p>\n\n\n\n

This type of class-level analysis is only possible because the stem system makes drug class identification systematic. Without reliable class identification through naming conventions, identifying all members of a drug class for patent expiration analysis would require reading the pharmacology sections of each drug’s prescribing information individually.<\/p>\n\n\n\n

Tracking New Stem Registrations as R&D Signals<\/h3>\n\n\n\n

The WHO and USAN Council register new stems when a genuinely novel drug class requires classification. The registration of a new stem is itself a competitive intelligence signal – it indicates that at least one company has a drug in the class far enough along to require INN designation, and the class is sufficiently novel that existing stems cannot accommodate it.<\/p>\n\n\n\n

The registration of “-gepant” as a new stem for CGRP receptor antagonists in the mid-2010s, for example, signaled ahead of first approval that multiple companies were developing compounds in this mechanistic class. The registration of “-cel” and related stems for CAR-T cell therapies signaled the emergence of cellular therapeutics as a commercially active class. The registration of “-degib” for hedgehog pathway inhibitors (vismodegib, sonidegib) signaled the therapeutic viability of smoothened receptor inhibition as an oncology target.<\/p>\n\n\n\n

Monitoring WHO Drug Information and USAN Council publications for new stem registrations is, in effect, a way to monitor the global pharmaceutical R&D community’s consensus about which new mechanisms are worth naming systematically.<\/p>\n\n\n\n

\n\n\n\n

Medication Safety and Naming Errors<\/h2>\n\n\n\n

When Similar Names Kill<\/h3>\n\n\n\n

Drug name confusion is not an academic concern. The ISMP maintains a regularly updated list of confused drug name pairs – drugs whose names look or sound alike and have been involved in dispensing or administration errors [27]. As of 2024, the list contains more than 400 such pairs, and a significant number involve generic drug names that are phonetically or orthographically similar to other generic names.<\/p>\n\n\n\n

The consequences range from minor – a patient receives the wrong strength of a drug in the same class – to lethal, when drugs with similar names have completely different therapeutic classes and dose ranges. The pair metformin\/metronidazole has generated dispensing errors because of the shared “meth-” initial syllable in some transcription contexts. Morphine\/hydromorphone errors are persistent because both are opioid analgesics with similar names and different dose equivalencies. Celebrex (celecoxib)\/Celexa (citalopram)\/Cerebyx (fosphenytoin) represents a three-way brand name confusion that the FDA identified and required labeling interventions to address, but the underlying generic name pairs celecoxib\/citalopram are also phonetically proximate.<\/p>\n\n\n\n

The public health cost of naming errors is substantial. A 2006 study published in JAMA estimated that preventable medication errors harm approximately 1.5 million Americans annually, with an excess healthcare cost of $3.5 billion [28]. Name-confusion errors are not the sole driver, but they are among the most systematically preventable causes.<\/p>\n\n\n\n

The FDA’s POCA Assessment Framework<\/h3>\n\n\n\n

The FDA’s Division of Medication Error Prevention and Analysis (DMEPA) reviews all proposed drug names – both brand and generic – under its POCA (Phonetic and Orthographic Computer Analysis) system before approval [15]. POCA generates a comprehensive list of existing drug names that are phonetically or visually similar to the proposed name, which DMEPA reviewers then evaluate for clinical confusion risk.<\/p>\n\n\n\n

A drug name that generates a large number of phonetically similar comparators from POCA must either be modified or accompanied by additional labeling and dispensing safeguards. The DMEPA has the authority to request name changes before approval, and pharmaceutical companies routinely engage in name vetting consultations before the formal submission process to avoid late-stage name rejections.<\/p>\n\n\n\n

For generic drug names specifically, the POCA review is conducted as part of the USAN Council’s processing. Names that pass USAN review have undergone at least one layer of systematic safety screening, but this does not guarantee that confusion risks will not emerge after approval when the name enters real-world clinical use contexts the reviewers did not anticipate.<\/p>\n\n\n\n

Tall Man Lettering: The Typographic Intervention<\/h3>\n\n\n\n

One established technique for reducing name confusion risk in clinical settings is “tall man lettering,” in which uppercase letters highlight the distinguishing portions of easily confused drug names. The FDA has published a list of drug name pairs for which it recommends tall man lettering on product labeling and in electronic prescribing systems [29].<\/p>\n\n\n\n

Examples include: buPROPion\/busPIRone (antidepressant versus anxiolytic), vinBLAStine\/vinCRIStine (vinca alkaloid cytotoxics with very different dose-limiting toxicity profiles), hydrALAzine\/hydrOXYzine (antihypertensive versus antihistamine), DOBUtamine\/DOPamine (inotropes with different receptor selectivity).<\/p>\n\n\n\n

The tall man lettering recommendation does not change the generic name itself – the letters highlighted in uppercase are not a formal naming convention but a safety annotation. However, the FDA’s recommendation creates a de facto labeling standard that generic manufacturers must follow for covered drug pairs, which affects packaging, labeling design, and electronic prescribing system configuration requirements.<\/p>\n\n\n\n

\n\n\n\n

The Orange Book, Purple Book, and Name-Based Drug Identification<\/h2>\n\n\n\n

How Generic Names Structure Orange Book Searches<\/h3>\n\n\n\n

The FDA’s Orange Book is organized by reference to the brand name of the approved drug product, but active ingredient searches use nonproprietary names. An analyst searching the Orange Book to identify all patents covering a drug that competes with a client’s development compound should search by the active ingredient’s nonproprietary name, not by any brand name.<\/p>\n\n\n\n

This matters because generic name searching in the Orange Book returns both the reference listed drug and any other approved products containing the same active ingredient (including combination products). If an analyst is assessing the patent landscape for a compound that shares an active ingredient with multiple approved combination products, a brand-name search would require multiple separate searches, while a nonproprietary name search returns the complete patent picture in a single query.<\/p>\n\n\n\n

DrugPatentWatch’s product pages are structured around the active ingredient’s nonproprietary name as the primary identifier, with brand names as associated attributes. This architecture allows analysts to assess the complete patent and exclusivity landscape for a drug substance across all its approved formulations and combination products simultaneously, which is precisely the comprehensive view needed for generic entry timing analysis.<\/p>\n\n\n\n

Purple Book and the Biologic INN Standard<\/h3>\n\n\n\n

The Purple Book, which covers FDA-approved biological products including biosimilars, uses a more complex naming structure that reflects the biosimilar-specific suffix policy described above. A Purple Book search for adalimumab returns not just the originator Humira but all approved biosimilars with their distinguishing suffixes: adalimumab-adaz, adalimumab-adbm, adalimumab-atto, adalimumab-bwwd, adalimumab-fkjp, and others approved as of 2024 [30].<\/p>\n\n\n\n

For patent analysis under the BPCIA’s patent dance framework, the suffix-level product identification in the Purple Book is the correct starting point for identifying which specific product a reference product sponsor must respond to in the 60-day exchange period following a biosimilar applicant’s notification. The INN alone is insufficient for BPCIA patent dance compliance, because different biosimilar applicants may have proposed different reference product designations, different manufacturing processes, and different claims of biosimilarity or interchangeability.<\/p>\n\n\n\n

\n\n\n\n

Nonproprietary Name Reform: Current Debates<\/h2>\n\n\n\n

The Combination Product Naming Problem<\/h3>\n\n\n\n

Current INN conventions for fixed-dose combination products have not kept pace with the growth of combination regimens in HIV, hepatitis C, tuberculosis, and oncology. The standard approach – listing both active ingredient INNs separated by a slash or “and” – creates unwieldy designations for multi-drug combinations.<\/p>\n\n\n\n

Bictegravir\/emtricitabine\/tenofovir alafenamide (Biktarvy, a three-drug HIV regimen) is a combination of three INNs, each with its own patent landscape, each subject to separate prior art and claim scope analysis, and each capable of being separated into individual components by generic manufacturers. The INN structure for this combination does not create a new patentable entity – the patents must cover each component or the combination itself as a separate composition – but it creates a regulatory naming convention that accurately reflects the compound nature of the product.<\/p>\n\n\n\n

As combination oncology regimens grow more complex, with three or four checkpoint inhibitors or targeted agents given in combination, the INN-listing approach will require continuing refinement. The WHO’s INN program is actively developing conventions for complex combination products, but no comprehensive reform has been finalized as of 2025.<\/p>\n\n\n\n

Stem System Capacity and Class Fragmentation<\/h3>\n\n\n\n

The stem system faces a capacity problem in highly crowded drug classes. The kinase inhibitor class, identified broadly by “-tinib,” now includes over 60 approved drugs [31]. While the “-tinib” suffix successfully identifies them all as kinase inhibitors, the class is mechanistically diverse – ALK inhibitors, EGFR inhibitors, BTK inhibitors, CDK inhibitors, and many others are all “-tinib” drugs, despite targeting entirely different kinases with entirely different selectivity profiles.<\/p>\n\n\n\n

The solution of creating subclass stems (as was done for CDK inhibitors with “-ciclib”) helps, but it requires ongoing stem system management and creates a proliferation of stems that only specialists can track. The alternative – using a single broad stem for all kinase inhibitors – sacrifices clinical information precision. The WHO’s INN Expert Group has not fully resolved this tension, and the stem list continues to grow more complex with each cohort of new approvals.<\/p>\n\n\n\n

The WHO Consultation and Transparency Gap<\/h3>\n\n\n\n

The WHO INN process is nominally open to public comment, but in practice the consultation period is short (four months), the WHO Drug Information publication has limited readership outside specialist communities, and the technical knowledge required to evaluate proposed names constructively is concentrated in the pharmaceutical industry itself.<\/p>\n\n\n\n

Several academic commentators have argued that the INN process should incorporate more systematic input from clinical end users – pharmacists, nurses, prescribers, and patients – who experience the real-world consequences of name confusion and name complexity [32]. The WHO’s Collaborating Centre for Patient Safety has called for expanded DMEPA-style phonetic and orthographic analysis to be formally integrated into the INN review process, rather than occurring independently in national jurisdictions after INN assignment.<\/p>\n\n\n\n

This reform would reduce the frequency of medication error-prone INN assignments but would also extend the timeline for INN designation, which creates complications for companies that need INN status before regulatory filing. The balance between safety review thoroughness and process efficiency has not been struck to broad satisfaction.<\/p>\n\n\n\n

\n\n\n\n

Practical Applications: Using Naming Data for IP Intelligence<\/h2>\n\n\n\n

Building a Stem-Based Pipeline Monitor<\/h3>\n\n\n\n

Analysts who track pharmaceutical competitive intelligence can build a systematic stem-based pipeline monitor using publicly available INN sources. The workflow uses four data streams together:<\/p>\n\n\n\n

WHO Drug Information proposed INN publications (quarterly) identify new compounds entering the INN process. USAN Council publication announcements in the AMA publications identify new U.S. designations. ClinicalTrials.gov registration records link new INNs to specific clinical programs and their sponsor companies. DrugPatentWatch’s patent family tracking links those INNs to the patent portfolios covering the same drug class, allowing rapid assessment of whether a new compound will enter a heavily or lightly patented competitive space.<\/p>\n\n\n\n

The integration of these four streams – name assignment, clinical development, and patent landscape – produces a structured competitive pipeline view that is more current and more comprehensive than relying on any single source.<\/p>\n\n\n\n

Generic Entry Timing from Naming and Patent Data<\/h3>\n\n\n\n

For generic manufacturers and their investors, the combination of nonproprietary name identification, Orange Book patent listing, and regulatory exclusivity data in platforms like DrugPatentWatch provides the foundational analysis for generic entry timing decisions.<\/p>\n\n\n\n

The analytical sequence is: identify the reference drug product by nonproprietary name, retrieve all Orange Book-listed patents covering that product, verify patent terms with PTA and PTE adjustments, overlay all applicable regulatory exclusivities (NCE, orphan, pediatric), identify any pending ANDA filings or Paragraph IV certifications from the FDA’s public database, and model the resulting entry timeline incorporating the probability of successful Paragraph IV litigation.<\/p>\n\n\n\n

The nonproprietary name is the entry point for this entire analysis. Without accurate, standardized nonproprietary name data that maps to the correct Orange Book entries, the subsequent patent and exclusivity retrieval steps produce unreliable outputs. This is precisely why naming accuracy is a data quality issue with direct commercial consequences, not merely a classification exercise.<\/p>\n\n\n\n

Cross-Border Patent Family Matching Using INN Standards<\/h3>\n\n\n\n

For international pharmaceutical patent portfolio analysis, INN provides the cross-border molecule identifier that enables patent family matching across jurisdictions. A European patent application designating “empagliflozin” and a Japanese patent application designating the JAN equivalent can be confirmed as covering the same molecule because both names are validated against the same INN, and the INN is linked to a CAS number and structural definition that allows definitive identity confirmation.<\/p>\n\n\n\n

Without the INN standard operating as a common reference, matching patent families across the forty or more national patent jurisdictions where major pharmaceutical companies file would require structure-by-structure chemical matching for every application, a substantially more resource-intensive process. The INN standard reduces this to a naming verification that takes seconds rather than minutes per patent family member.<\/p>\n\n\n\n

\n\n\n\n

Reference Tables: Key Stems for Pharmaceutical Professionals<\/h2>\n\n\n\n

Quick-Reference Stem Glossary<\/h3>\n\n\n\n

The following table presents the stems most frequently encountered in pharmaceutical IP and competitive intelligence work, organized by therapeutic category. This is not exhaustive – the full WHO stem list runs to over 400 entries – but covers the stems that appear in the majority of commercially significant drugs in active patent analysis.<\/p>\n\n\n\n

Cardiovascular and Renal:<\/strong> “-olol” identifies beta-adrenoreceptor antagonists (propranolol, atenolol, metoprolol). “-pril” identifies ACE inhibitors (captopril, enalapril, lisinopril). “-sartan” identifies angiotensin II receptor antagonists (losartan, valsartan, irbesartan). “-vastatin” identifies HMG-CoA reductase inhibitors (lovastatin, atorvastatin, rosuvastatin). “-dipine” identifies dihydropyridine calcium channel blockers (nifedipine, amlodipine). “-flozin” identifies SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin).<\/p>\n\n\n\n

Anti-infectives:<\/strong> “-cillin” identifies penicillin-class antibiotics. “-cef-\/ceph-” identifies cephalosporins. “-penem” identifies carbapenems. “-cycline” identifies tetracyclines. “-conazole” identifies azole antifungals. “-vir” identifies antivirals (broad). “-navir” identifies HIV protease inhibitors. “-tegravir” identifies HIV integrase inhibitors. “-previr” identifies hepatitis C NS3\/4A protease inhibitors. “-asvir” identifies hepatitis C NS5A inhibitors. “-buvir” identifies hepatitis C NS5B polymerase inhibitors.<\/p>\n\n\n\n

Oncology:<\/strong> “-tinib” identifies kinase inhibitors broadly. “-ciclib” identifies CDK4\/6 inhibitors. “-rafenib” identifies BRAF inhibitors. “-metinib” identifies MEK inhibitors. “-lisib” identifies PI3K inhibitors. “-sertib” identifies PARP inhibitors. “-zomib” identifies proteasome inhibitors. “-mab” identifies monoclonal antibodies. “-umab” identifies human monoclonal antibodies (pre-2021 naming). “-zumab” identifies humanized monoclonal antibodies (pre-2021 naming). “-ximab” identifies chimeric monoclonal antibodies (pre-2021 naming).<\/p>\n\n\n\n

CNS and Pain:<\/strong> “-azepam” identifies benzodiazepines with that ring structure. “-triptan” identifies 5-HT1B\/1D receptor agonists (migraine). “-gepant” identifies CGRP receptor antagonists. “-barbital” identifies barbiturates. “-tine” appears in several SSRI names.<\/p>\n\n\n\n

Metabolic:<\/strong> “-gliptin” identifies DPP-4 inhibitors. “-glutide” identifies GLP-1 receptor agonists. “-gliflozin” (same as “-flozin” variant) identifies SGLT2 inhibitors.<\/p>\n\n\n\n

Biologics and Advanced Therapies:<\/strong> “-mab” identifies monoclonal antibodies. “-cept” identifies fusion proteins (etanercept, abatacept, rilonacept). “-ase” identifies enzymes (alteplase, laronidase). “-kin” identifies interleukin-class cytokines (aldesleukin, denileukin). “-cel” appears in CAR-T cell therapies (axicabtagene ciloleucel, tisagenlecleucel).<\/p>\n\n\n\n

\n\n\n\n

Case Study: Decoding a New Drug Name in Real Time<\/h2>\n\n\n\n

Applying the Framework to a Current Pipeline Compound<\/h3>\n\n\n\n

To illustrate how naming convention knowledge functions in practice, consider the analytical process for a hypothetical new compound name appearing in a WHO Drug Information proposed INN list: “telabaxinib.”<\/p>\n\n\n\n

Reading from right to left (starting from the stem): “-tinib” places this compound in the kinase inhibitor class. The infix “-bax-” or the full “-baxin-” portion before “-tinib” would be checked against known infix conventions – “-bax-” does not correspond to an established target-specific subgroup stem, which suggests either a new target category or a compound in a target class that has not yet developed a subgroup stem.<\/p>\n\n\n\n

The prefix “tela-” is invented and carries no inherent meaning. It distinguishes this compound from other kinase inhibitors within the class.<\/p>\n\n\n\n

Next steps in the analysis: search ClinicalTrials.gov for registered trials using the compound name or its synonyms to identify the therapeutic indication and sponsor. Search DrugPatentWatch for patents in the “-tinib” class filed by the suspected sponsor company within the past five to seven years (INN application timing correlates with late preclinical\/early Phase I). Review the WHO INN submission for the compound’s pharmacological description, which will identify the specific kinase target and enable comparison with existing patent claims in that target space.<\/p>\n\n\n\n

Within an hour of seeing “telabaxinib” on the proposed INN list, a knowledgeable analyst can identify the compound class, likely sponsor, therapeutic focus, and patent landscape context. The same analysis without naming convention fluency would take a day or more of non-systematic searching.<\/p>\n\n\n\n

\n\n\n\n

Conclusion: Fluency That Pays<\/h2>\n\n\n\n

Generic drug naming is a structured language. Its grammar is the stem system. Its vocabulary is the accumulated list of assigned nonproprietary names and their embedded pharmacological meanings. Its governing institutions are the WHO INN Expert Group and the USAN Council, operating under international coordination frameworks that have steadily improved since the foundational WHO resolution of 1950.<\/p>\n\n\n\n

For pharmaceutical professionals – IP analysts, patent attorneys, regulatory strategists, competitive intelligence researchers, and generic manufacturers – fluency in this language is a practical professional competence with measurable value. Reading a proposed INN list and extracting actionable competitive intelligence requires knowing stems. Evaluating a biosimilar patent portfolio under BPCIA requires understanding the suffix policy and its implications. Tracing historical prior art through multi-jurisdiction patent families requires knowing how to reconcile divergent national name designations. Assessing medication safety risk in a new formulation requires understanding the DMEPA review process and the ISMP’s confused name list.<\/p>\n\n\n\n

None of these capabilities require advanced chemistry training. They require systematic familiarity with a naming architecture that is both publicly documented and readily learnable. The investment in that familiarity pays dividends every time a new proposed INN appears in WHO Drug Information, every time an Orange Book search turns on the correct nonproprietary name designation, and every time an international patent family needs to be mapped against a drug substance whose name varies across jurisdictions.<\/p>\n\n\n\n

The pharmaceutical alphabet, properly decoded, reads clearly.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n

International Nonproprietary Names (INNs) and United States Adopted Names (USANs) are largely harmonized but not identical, and analysts should be aware of historical divergences for drugs approved before 1995.<\/p>\n\n\n\n

The INN stem system embeds pharmacological class information directly into every generic drug name. The stems “-tinib,” “-mab,” “-sartan,” “-pril,” “-flozin,” and approximately 400 others each correspond to specific drug classes, mechanisms of action, or structural families.<\/p>\n\n\n\n

INN publication constitutes a public disclosure event with patent law implications. The timing of INN application submission relative to patent filing is a strategic decision, not merely an administrative one.<\/p>\n\n\n\n

The 2021 WHO reform of monoclonal antibody naming eliminated the source substem (the “u-\/zu-\/xi-” designations indicating human, humanized, or chimeric origin) for new INNs assigned after the effective date. Pre-2021 antibody names retain their original format.<\/p>\n\n\n\n

The FDA’s four-letter biosimilar suffix policy (e.g., adalimumab-adaz) has pharmacovigilance justification but also creates market differentiation between originator biologics and their biosimilar competitors. The policy has direct implications for Purple Book patent tracking and BPCIA patent dance compliance.<\/p>\n\n\n\n

Proposed INN publications in WHO Drug Information are a legitimate competitive intelligence source, providing six-to-twelve months of advance notice about drug development programs ahead of clinical trial registration and marketing applications.<\/p>\n\n\n\n

Stem-based pipeline analysis – combining new INN monitoring with DrugPatentWatch patent family tracking and ClinicalTrials.gov registration data – allows systematic competitive landscape mapping for entire drug classes, not just individual compounds.<\/p>\n\n\n\n

The ISMP’s confused drug name list and FDA’s POCA assessment system identify naming safety risks that pharmaceutical manufacturers must address before approval. Generic names that generate numerous phonetically similar comparators face heightened regulatory scrutiny.<\/p>\n\n\n\n

Modified INNs (INNMs) designate salt and ester forms of drug substances. Orange Book patent coverage of a specific salt form is legally distinct from coverage of the free base compound, which is relevant in Paragraph IV patent challenges involving salt form patents.<\/p>\n\n\n\n

Country-specific name designations (USAN, BAN, JAN) require reconciliation against INN when tracking international patent families. Misidentification of the active ingredient through name variant confusion is a data quality risk with direct impact on patent coverage analysis.<\/p>\n\n\n\n

CAR-T cell therapies, ADCs, and bispecific antibodies have each required extensions and modifications to the standard INN naming architecture, creating compound names whose structure requires class-specific decoding beyond the basic stem framework.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/h2>\n\n\n\n

Q1: If a company changes its drug from a racemate to a single enantiomer formulation, does it receive an entirely new INN, and how does this interact with patent strategy?<\/strong><\/p>\n\n\n\n

A1: Single enantiomer compounds receive new INNs distinct from the racemate INN, but the naming conventions signal the relationship. The convention is to add a chirality prefix – typically “es-” for S-enantiomers, “lev-” or “l-” for laevorotatory forms – to a prefix element derived from the racemate’s name. Omeprazole (racemate) became esomeprazole (S-enantiomer). Citalopram (racemate) became escitalopram (S-enantiomer). Ofloxacin became levofloxacin. The new INN is a clear public signal that a chiral switch strategy is underway. From a patent perspective, this matters because the chiral switch is one of the most scrutinized forms of line extension. If the S-enantiomer is pharmacologically active and the R-enantiomer is inactive or less active, a compound patent covering the racemate may or may not cover the individual enantiomer under a narrow claim construction. New patents covering the enantiomer specifically are frequently filed, and their patentability over the racemate is determined by whether separating the enantiomer was obvious from prior art suggesting its superior activity profile. The INN assignment itself, by publicly naming the enantiomer with a chirality prefix, can constitute prior art for any patent application filed after the INN publication.<\/p>\n\n\n\n

Q2: How does DrugPatentWatch use generic drug names to structure its patent-to-product linkages, and what are the practical limits of that linkage?<\/strong><\/p>\n\n\n\n

A2: DrugPatentWatch uses the nonproprietary name as the primary identifier linking drug products to their Orange Book and Purple Book patent listings, ANDA filing records, and Paragraph IV litigation history. The practical value of this architecture is that an analyst searching by active ingredient name can retrieve the complete regulatory and patent landscape for that molecule across all approved formulations without separate brand-name searches. The limits of this linkage reflect the limits of the underlying data: Orange Book self-certification means that listed patents may not accurately cover the listed drug product (over-listing), and the linkage between patent number and drug substance depends on FDA listing accuracy rather than independent verification of claim coverage. For high-stakes decisions – generic entry timing analysis, acquisition due diligence, litigation strategy – the name-based database linkage is the starting point, not the conclusion. Claim-level coverage analysis requires attorney review against the actual product and patent text, which the database identifies but cannot perform autonomously.<\/p>\n\n\n\n

Q3: What happens when an INN application is rejected, and how does a pharmaceutical company proceed?<\/strong><\/p>\n\n\n\n

A3: Outright rejection of an INN application is rare – the WHO’s standard response to a problematic proposed name is to propose an alternative rather than reject the application. A company whose proposed name is rejected or substantially modified has limited appeal options within the INN process. The WHO’s INN Expert Group decision is final within the INN process, though companies can provide additional technical arguments during the comment period and in response to proposed rINNs they find unsatisfactory. In practice, most INN assignment disputes are resolved through negotiation during the pre-publication phase, before the formal proposed rINN is published. The USAN Council process is somewhat more iterative – companies can engage in multiple rounds of discussion with Council staff before a name is finalized, allowing for cooperative resolution of naming conflicts. Where INN and USAN processes reach different conclusions – an increasingly rare outcome given harmonization but not impossible – the company may end up with different names in different regulatory contexts, requiring explicit cross-referencing in all regulatory submissions.<\/p>\n\n\n\n

Q4: How does the stem system handle drugs that have multiple mechanisms of action, and does dual-mechanism classification affect patentability or claim drafting?<\/strong><\/p>\n\n\n\n

A4: The stem system assigns a single stem based on the primary mechanism of action, even for drugs with confirmed secondary mechanisms. When a drug’s commercial differentiation or therapeutic rationale specifically depends on dual mechanism, naming bodies may assign an infix reflecting the secondary activity alongside the primary stem. Carvedilol, for example, carries both “-dil” (vasodilator activity through alpha-1 receptor blockade) and “-olol” (beta-blockade) elements in its name – the “carve-” prefix plus “-di-” infix plus the beta-blocker “-olol” stem encodes the dual activity. For patent strategy, the dual-mechanism drug presents a distinct challenge: a patent claiming the compound solely based on beta-blockade would not necessarily differentiate the compound from simpler beta-blockers, so the inventive step in patenting such a compound rests on demonstrating that the combination of activities was non-obvious. This means patent drafts for dual-mechanism compounds should claim both activities in combination claims, and the specification should include data demonstrating synergy or clinical advantage from the combined activity rather than simply asserting it. The INN naming that reflects both mechanisms, when published before a patent application’s filing date, can constitute prior art for the single-activity aspects of the claim while leaving the dual-activity combination potentially patentable if adequately supported.<\/p>\n\n\n\n

Q5: Is it possible for a generic drug name to be used as evidence of prior disclosure in an IPR proceeding, and what are the standards for doing so?<\/strong><\/p>\n\n\n\n

A5: INN designations can function as prior art in IPR proceedings, but the evidentiary value depends on what the INN publication actually disclosed. An INN listing in WHO Drug Information typically discloses the drug’s name, its pharmacological class (through the stem), a chemical name or description, and sometimes a brief pharmacological description. What it does not necessarily disclose in full is: the complete chemical structure, synthetic routes, specific biological activity data, dose ranges, or formulation details. In an IPR challenging a pharmaceutical patent on obviousness grounds, an INN publication can establish that the compound or its pharmacological class was known before the patent’s filing date and can anchor a motivation-to-combine argument if it is combined with other prior art providing the structural and activity details. For an anticipation argument under 35 U.S.C. \u00a7 102, an INN publication alone rarely provides sufficient structural specificity to literally disclose every claim element. The more complete INN submission documentation – which includes structural data – might provide higher-quality prior art, but access to submission records requires a formal request to the WHO, and their publication status varies. IPR petitioners who want to use INN-based prior art should verify the completeness of the public disclosure against the specific claim elements being challenged before relying on the INN listing as the primary prior art reference.<\/p>\n\n\n\n

\n\n\n\n

Sources<\/h2>\n\n\n\n

[1] International Union of Pure and Applied Chemistry. (2013). Nomenclature of organic chemistry: IUPAC recommendations and preferred names 2013<\/em>. Royal Society of Chemistry. https:\/\/doi.org\/10.1039\/9781849733069<\/p>\n\n\n\n

[2] World Health Organization. (2006). INN in use: A guide to the use of WHO International Nonproprietary Names for pharmaceutical substances<\/em>. WHO.<\/p>\n\n\n\n

[3] Aronson, J. K. (2000). Where name and image meet – the argument for “adrenaline.” BMJ, 320<\/em>(7233), 506-509. https:\/\/doi.org\/10.1136\/bmj.320.7233.506<\/p>\n\n\n\n

[4] American Medical Association. (2021). USAN Council: History and purpose<\/em>. AMA. https:\/\/www.ama-assn.org\/about\/ama-councils\/ama-council-drug-nonproprietary-names<\/p>\n\n\n\n

[5] United States Adopted Name Council. (2020). Statement on nonproprietary nomenclature<\/em>. American Medical Association.<\/p>\n\n\n\n

[6] World Health Organization. (2022). International Nonproprietary Names: Cumulative list no. 14<\/em>. WHO. https:\/\/www.who.int\/publications\/i\/item\/9789240042674<\/p>\n\n\n\n

[7] World Health Organization Expert Committee on Drug Dependence. (1997). Omeprazole. In WHO Drug Information, 11<\/em>(2). WHO.<\/p>\n\n\n\n

[8] Brittain, H. G. (Ed.). (1999). Analytical profiles of drug substances and excipients<\/em> (Vol. 26). Academic Press.<\/p>\n\n\n\n

[9] Nelson, M. L., & Levy, S. B. (2011). The history of the tetracyclines. Annals of the New York Academy of Sciences, 1241<\/em>(1), 17-32. https:\/\/doi.org\/10.1111\/j.1749-6632.2011.06354.x<\/p>\n\n\n\n

[10] Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV<\/em>. U.S. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines<\/p>\n\n\n\n

[11] Dodick, D. W. (2019). CGRP ligand and receptor monoclonal antibodies for migraine prevention. Headache: The Journal of Head and Face Pain, 59<\/em>(Suppl. 2), 1-2. https:\/\/doi.org\/10.1111\/head.13659<\/p>\n\n\n\n

[12] Bhullar, K. S., Lagar\u00f3n, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018). Kinase-targeted cancer therapies: Progress, challenges and future directions. Molecular Cancer, 17<\/em>(1), 48. https:\/\/doi.org\/10.1186\/s12943-018-0804-2<\/p>\n\n\n\n

[13] World Health Organization. (2018). Procedure for the selection of recommended International Nonproprietary Names for pharmaceutical substances<\/em>. WHO\/EMP\/RHT\/TSN\/2018.1. WHO.<\/p>\n\n\n\n

[14] Institute for Safe Medication Practices. (2023). ISMP list of confused drug names<\/em>. ISMP. https:\/\/www.ismp.org\/recommendations\/confused-drug-names-list<\/p>\n\n\n\n

[15] U.S. Food and Drug Administration. (2016). Best practices for the naming, labeling, and packaging of drug products to minimize medication errors: Guidance for industry<\/em>. FDA. https:\/\/www.fda.gov\/media\/84001\/download<\/p>\n\n\n\n

[16] Dillman, R. O. (2011). Perceptions of Herceptin: A monoclonal antibody for the treatment of breast cancer. Cancer Biotherapy and Radiopharmaceuticals, 26<\/em>(2), 109-126. https:\/\/doi.org\/10.1089\/cbr.2010.0876<\/p>\n\n\n\n

[17] World Health Organization. (2021). Revised monoclonal antibody (mAb) nomenclature scheme<\/em>. WHO Drug Information, 35(1). WHO. https:\/\/www.who.int\/publications\/m\/item\/revised-mab-nomenclature-scheme<\/p>\n\n\n\n

[18] World Health Organization. (2022). Monoclonal antibody (mAb) INN nomenclature<\/em>. WHO. https:\/\/www.who.int\/teams\/health-product-and-policy-standards\/inn\/mabs<\/p>\n\n\n\n

[19] Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020). Antibody-drug conjugates: A comprehensive review. Molecular Cancer Research, 18<\/em>(1), 3-19. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0582<\/p>\n\n\n\n

[20] Krishnamurthy, A., & Jimeno, A. (2018). Bispecific antibodies for cancer therapy: A review. Pharmacology & Therapeutics, 185<\/em>, 122-134. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.12.002<\/p>\n\n\n\n

[21] U.S. Food and Drug Administration. (2015). Nonproprietary naming of biological products: Draft guidance for industry<\/em>. FDA. https:\/\/www.fda.gov\/media\/86121\/download<\/p>\n\n\n\n

[22] GPhA & BPIA. (2015). Comments to the FDA on nonproprietary naming of biological products<\/em>. Generic Pharmaceutical Association.<\/p>\n\n\n\n

[23] 35 U.S.C. \u00a7 102. (2024). Conditions for patentability; novelty<\/em>. United States Code.<\/p>\n\n\n\n

[24] World Health Organization. (1997). International drug monitoring: The role of national centres<\/em>. WHO Technical Report Series No. 498. WHO.<\/p>\n\n\n\n

[25] Abbott Laboratories v. Andrx Pharmaceuticals, Inc., 452 F.3d 1331 (Fed. Cir. 2006).<\/p>\n\n\n\n

[26] World Health Organization. (2024). WHO Drug Information: International Nonproprietary Names<\/em>. WHO. https:\/\/www.who.int\/publications\/journals\/drug-information<\/p>\n\n\n\n

[27] Institute for Safe Medication Practices. (2024). ISMP’s list of confused drug names<\/em>. ISMP. https:\/\/www.ismp.org\/recommendations\/confused-drug-names-list<\/p>\n\n\n\n

[28] Aspden, P., Wolcott, J., Bootman, J. L., & Cronenwett, L. R. (Eds.). (2006). Preventing medication errors: Quality chasm series<\/em>. National Academies Press. https:\/\/doi.org\/10.17226\/11623<\/p>\n\n\n\n

[29] U.S. Food and Drug Administration. (2020). Tall Man (mixed case) letters<\/em>. FDA. https:\/\/www.fda.gov\/drugs\/medication-errors-related-cder-regulated-drug-products\/tall-man-mixed-case-letters<\/p>\n\n\n\n

[30] U.S. Food and Drug Administration. (2024). Purple Book: Lists of licensed biological products<\/em>. FDA. https:\/\/purplebooksearch.fda.gov\/<\/p>\n\n\n\n

[31] Cohen, P., Cross, D., & Janne, P. A. (2021). Kinase drug discovery 20 years after imatinib: Progress and future directions. Nature Reviews Drug Discovery, 20<\/em>(7), 551-569. https:\/\/doi.org\/10.1038\/s41573-021-00195-4<\/p>\n\n\n\n

[32] Aronson, J. K. (2004). Confusion over similar drug names: Problems and solutions. Expert Opinion on Drug Safety, 3<\/em>(2), 167-172. https:\/\/doi.org\/10.1517\/14740338.3.2.167<\/p>\n","protected":false},"excerpt":{"rendered":"

The Name Behind the Molecule Every drug in clinical use has at least three names. There is the brand name, […]<\/p>\n","protected":false},"author":1,"featured_media":37112,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37110"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37110\/revisions"}],"predecessor-version":[{"id":37113,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37110\/revisions\/37113"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37112"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}